Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Accured Expenses (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Change in Accured Expenses for 6 consecutive years, with -$4.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 176.38% to -$4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.3 million, a 42.11% increase, with the full-year FY2025 number at $6.3 million, up 42.11% from a year prior.
  • Change in Accured Expenses was -$4.5 million for Q4 2025 at Janux Therapeutics, down from $6.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $6.2 million in Q3 2025 to a low of -$4.5 million in Q4 2025.
  • A 5-year average of $861100.0 and a median of $971500.0 in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 605.87% in 2022, then crashed 483.57% in 2024.
  • Janux Therapeutics' Change in Accured Expenses stood at $1.9 million in 2021, then plummeted by 47.68% to $1.0 million in 2022, then plummeted by 57.61% to $426000.0 in 2023, then plummeted by 483.57% to -$1.6 million in 2024, then plummeted by 176.38% to -$4.5 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Change in Accured Expenses are -$4.5 million (Q4 2025), $6.2 million (Q3 2025), and $2.9 million (Q2 2025).